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carbohydrate and protein diet. The patient suffering an acute attack may not be able to take a high carbohydrate, high protein diet and the author has made preliminary observations on the use of concentrated lkvulose intravenously in a severe attack. Four pints of 20 % 1kevulose were given intravenously. Between each bottle half a pint of normal saline was given I.V. to avoid thrombosis of the vein. There was clinical improvement and a fall in the urinary 8-amino levulic acid, porphobilinogen and urinary uroporphyrin in 2 instances. Renal hemodialysis has been used in a few cases of acute intermittent porphyria (Rees et al. 1967) . There is in fact no real evidence that there is a circulating toxic factor present in the blood which causes symptoms; the porphyrins themselves and their precursors are nontoxic. It is more likely that the clinical manifestations are caused by some underlying biochemical disorder, associated with the hepatic defect in the acute types of porphyria. In one patient with porphyria variegata who was in coma the dialysis was followed by a significant fall in the level of 8-amino levulic acid, porphobilinogen and uroporphyrin, and marked improvement of the clinical state.
Summary
There is still no rational method for a fundamental approach to the treatment of the porphyrias, but a great deal has been done already in lowering the mortality rate. Death in the past has been caused by respiratory failure and terminal bronchopneumonia and the use of tracheostomy and intermittent positive pressure techniques and chemotherapy has undoubtedly been responsible for the diminution of mortality. The two most important points in the management of acute porphyria are rapid diagnosis for those affected and the detection of latent porphyria among their families. Although qualitative tests for the detection of porphyrins and the precursors in the urine and stool are helpful it is now recognized that quantitative studies are necessary to define clearly the latent case (Lancet 1967 One of the more powerful tools in photobiology is so-called 'action spectroscopy', the relating of biological response to wavelength and dose of radiation. It is important because it is based on a fundamental principle of photochemistry, the Grotthus-Draper law. This states that wavelengths that are absorbed will activate a substance susceptible to photochemical change; those wavelengths that are not absorbed will not activate it.
To forecast what wavelengths should be reactive, we need to know the absorption spectrum of the photosensitizer, where its identity is known. Where the photosensitizer is not known, one hopes to recognize it from comparing the results of action spectroscopy with the absorption spectra of known substances.
In action spectroscopy of the skin one relates the activity of a skin response to the wavelength and dose of the radiation; the result is called an 'action spectrum'. This sort of work started with the pioneer studies of Hausser & Vable (1921) in Germany on the sunburn response in normal skin. Human skin is very reactive to shorter ultraviolet wavelengths and a polykymatic emitter, e.g. mercury arc, of modest power is here sufficient as a source for a small irradiation monochromator. The action spectrum shows that the most effective wavelength in terrestrial sunlight for sunburn is at about 300 nm; wavelengths longer than about 320 nm, however, had very little erythemal action.
The study of the action spectrum of the skin of patients with porphyria is, however, recent. Before this explanations of the mechanism of the photosensitivity associated with these diseases were controversial and mostly unsatisfactory. It is ironical to note, however, that the photobiological mechanism underlying porphyria in sheep was well understood.
But the position over human porphyria changed with the ready commercial availability of the high pressure xenon arc about ten years ago.
Using this arc, a number of high-intensity irradiation monochromators have been developed at the Institute of Dermatology, London, and elsewhere, especially in the USA.
Patients with porphyria who may be clinically photosensitive include those with hepatic cutaneous porphyria, variegate porphyria and the rare congenital porphyria, but not acute intermittent independently confirmed these findings on patients with hepatic cutaneous porphyiia and the porphyria. The porphyrin compounds which are of interest because of their in vitro photosensitizing potential, include uro-, copro-and protoporphyrin; all have similar absorption spectra in visible light (Fig 1) . There is a strong peak of absorption at about 400 nm (violet light), with somewhat lesser peaks between 500 and 625 nm (green-yellow light). On the other hand absorption at 300 nm, where the normal sunburn reaction occurs, is very slight. Thus, according to the Grotthus-Draper law, the skin of a patient with porphyria should react to wavelengths of visible light that produce no significant erythemal reactions in normal persons. Such an abnormal type of skin photosensitization had, in fact, been shown to obtain in porphyric sheep as long ago as 1941 by Riemerschmid & Quin, who used strong South African sunlight and absorption filters to delimit the spectral photosensitivity in the disorder known as geeldikkop. The photosensitivity here is due to the porphyrin phylloerythrin and the condition may be reproduced experimentally in guinea-pigs, as shown recently by Mr Peter Bremner working in the Photobiology Department of the Institute of Dermatology, London.
Photosensitive humans with porphyria were first tested with monochromatic light about ten years ago; it was then at last possible to show that the Grotthus-Draper law held in this disease even for human skin (Magnus et al. 1959 ). These were patients with hepatic cutaneous porphyria; maximum photosensitivity was at 400 nm, with lesser reactivity between 500 and 600 nm (see Fig 1) . Wiskemann & Wulf (1959) in Hamburg About eight years ago, other photosensitive patients, who were not sent in with a diagnosis of porphyria, showed action spectra that were recognized as identical to those in hepatic cutaneous porphyria. Yet they certainly did not have this disease and were excreting entirely normal amounts of porphyrin in the urine. It was evident that we were dealing with an overlooked type of porphyria, now known as erythropoietic protoporphyria (Magnus et al. 1961) . Langhof et al. (1961) also recognized this condition independently at about the same time.
A not unimportant, if negative, contribution of photobiology to practical medicine has been in the management of photosensitivity; it is at once clear from the action spectra that standard light barrier preparations, which absorb sunburn wavelengths only (i.e. near 300 nm), are useless in porphyria; patients just have to keep out of the sun and there is no specific treatment for the skin. A perhaps more positive contribution was in the correct diagnosis of cases that had been incorrectly labelled as being psychoneurotic; these were usually examples of erythropoietic protoporphyria with marked symptoms but little or no signs of photosensitivity. Another contribution was in clearing up the confusion over the photosensitivity in so-called 'atypical' lipoid proteinosis; this was due to the fact that lipoid proteinosis had been confused for porphyria, owing to their similar histological picture. I will conclude with some work done in collaboration with A C Allison and M R Young. It had been found that certain photosensitizers are stored in the lysosomes of tissue culture cells. So we studied the effect of monochromatic radiation on tissue cultures that had been treated with porphyrin. The action spectrum for cell death in the cultures was found to be exactly the same as that for lesions in the skin of patients with porphyria. In addition it was found that molecular oxygen is essential for this lethal action; thus the initial photochemical reaction would seem to be of so-called photodynamic type (Blum 1941 ). Furthermore, one of the earliest signs of damage in a photosensitized cell was leakage of the hydrolytic enzymes from the lysosome into the cell. It is thus postulated that the release of these enzymes plays a part in the formation of lesions in the skin due to light (Allison et al. 1966 , Slater & Riley 1966 .
Taking the photochemical results of Oster et al. (1959) , we suggest a hypothesis for the photosensitizing mechanism in porphyria as follows: 
